November 17, 2015
Study: Janssen’s OLYSIO safe for treating hepatitis C virus Patients (Egypt)
The OSIRIS trial Phase II a investigating once daily OLYSIO (simeprevir) in combination with sofosbuvir in hepatitis C virus (HCV) genotype 4 infected patients, with and without liver cirrhosis, demonstrated treatment to be safe.